Diviti pre-filled syringes
Ingredients in every 0.5 ml
Each package contains
|ATC Level 1||B - Blood and blood forming organs|
|ATC Level 2||B01 - Antithrombotic Agents|
|ATC Level 3||B01A - Antithrombotic Agents|
17 TO 75 YEARS OLD
Orthopedic and abdominal surgery:
The recommended dose of fondaparinux sodium is 2.5 mg once daily, administered postoperatively by subcutaneous injection.
The timing of the first dose should be no earlier than 6 hours following surgical closure, and only after hemostasis has been established.
Duration of treatment usually until the patient is ambulant, at least 5 to 9 days after surgery.
Medical patients at risk of thromboembolic complications:
The recommended dose of fondaparinux sodium is 2.5 mg once daily administered by subcutaneous injection. Treatment duration is about 6 to 14 days.
0 TO 17 YEARS OLD
The safety and efficacy of fondaparinux sodium in patients under the age of 17 has not been established.
75 YEARS OLD AND ABOVE
Fondaparinux sodium should be used with caution in elderly patients as renal function decreases with age.
PATIENTS WITH RENAL IMPAIRMENT
Fondaparinux sodium should not be used in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage reduction is required for patients with mild or moderate renal impairment.
PATIENTS WITH HEPATIC IMPAIRMENT
No dosing adjustment of fondaparinux sodium is necessary. In patients with severe hepatic impairment, fondaparinux sodium should be used with caution.
PATIENTS WITH BODY WEIGHT LESS THAN 50 KG
Patients with body weight less than 50 kg are at increased risk of bleeding. For prophylaxis following surgery fondaparinux sodium should be used with caution in these patients.
– Prevention of venous thromboembolic events (VTE) in patients undergoing major orthopedic surgery of the lower limbs such as hip fracture including extended prophylaxis, knee replacement surgery, hip replacement surgery.
– Prevention of venous thromboembolic events (VTE) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.
– Prevention of venous thromboembolic events (VTE) in medical patients who are at risk for VTE and who are thromboembolic complications due to restricted mobility during acute illness.